403 related articles for article (PubMed ID: 20564754)
1. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
[TBL] [Abstract][Full Text] [Related]
2. Value of liver biopsy in the diagnosis of drug-induced liver injury.
Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
[TBL] [Abstract][Full Text] [Related]
3. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
Fontana RJ; Watkins PB; Bonkovsky HL; Chalasani N; Davern T; Serrano J; Rochon J;
Drug Saf; 2009; 32(1):55-68. PubMed ID: 19132805
[TBL] [Abstract][Full Text] [Related]
4. Causality assessment in drug-induced liver injury.
Hayashi PH
Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
[TBL] [Abstract][Full Text] [Related]
5. Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record.
Yeboah-Korang A; Louissaint J; Tsung I; Prabhu S; Fontana RJ
Drug Saf; 2020 Apr; 43(4):371-377. PubMed ID: 31916081
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of idiosyncratic drug-induced liver injury.
Hassan A; Fontana RJ
Liver Int; 2019 Jan; 39(1):31-41. PubMed ID: 30003672
[TBL] [Abstract][Full Text] [Related]
7. Review article: clinical assessment of suspected drug-induced liver injury and its management.
Vuppalanchi R; Ghabril M
Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1516-1531. PubMed ID: 36282208
[TBL] [Abstract][Full Text] [Related]
8. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
9. Drug induced liver injury: an update.
Garcia-Cortes M; Robles-Diaz M; Stephens C; Ortega-Alonso A; Lucena MI; Andrade RJ
Arch Toxicol; 2020 Oct; 94(10):3381-3407. PubMed ID: 32852569
[TBL] [Abstract][Full Text] [Related]
10. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.
Fontana RJ
Gastroenterology; 2014 Apr; 146(4):914-28. PubMed ID: 24389305
[TBL] [Abstract][Full Text] [Related]
12. Case definition and phenotype standardization in drug-induced liver injury.
Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.
Shen T; Liu Y; Shang J; Xie Q; Li J; Yan M; Xu J; Niu J; Liu J; Watkins PB; Aithal GP; Andrade RJ; Dou X; Yao L; Lv F; Wang Q; Li Y; Zhou X; Zhang Y; Zong P; Wan B; Zou Z; Yang D; Nie Y; Li D; Wang Y; Han X; Zhuang H; Mao Y; Chen C
Gastroenterology; 2019 Jun; 156(8):2230-2241.e11. PubMed ID: 30742832
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury.
Fontana RJ; Bjornsson ES; Reddy R; Andrade RJ
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2088-2099. PubMed ID: 36868489
[TBL] [Abstract][Full Text] [Related]
15. Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults.
Yeboah-Korang A; Memon A; Patel N; Portocarrero-Castillo A; Osman A; Kleesattel D; Lopez C; Louissaint J; Sherman K; Fontana R
Dig Dis Sci; 2022 Nov; 67(11):5262-5271. PubMed ID: 35122190
[TBL] [Abstract][Full Text] [Related]
16. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M; Kleiner DE; Goodman Z; Brunt E; Avigan MI; Regev A; Hayashi PH; Lewis JH; Mehta R; Harrison SA; Siciliano M; McWherter CA; Vuppalanchi R; Behling C; Miller V; Chalasani N; Sanyal AJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):201-216. PubMed ID: 37877759
[TBL] [Abstract][Full Text] [Related]
17. An update on drug induced liver injury.
Rangnekar AS; Fontana RJ
Minerva Gastroenterol Dietol; 2011 Jun; 57(2):213-29. PubMed ID: 21587150
[TBL] [Abstract][Full Text] [Related]
18. Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
Hussaini SH; Farrington EA
Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714
[TBL] [Abstract][Full Text] [Related]
19. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
20. RUCAM in Drug and Herb Induced Liver Injury: The Update.
Danan G; Teschke R
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
